Abstract
Nivolumab, a human IgG4 programmed death 1 (PD-1) immune checkpoint–inhibitor antibody, disrupts PD-1–mediated signaling and restores antitumor immunity (1). Many recent studies have emphasized the importance of anti–PD-1 antibodies to improve survival outcomes among patients with advanced melanoma or lung cancer. Several endocrinological side effects have been reported and a few patients developed insulin-requiring diabetes (2). Some …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
